Distinctive vasculopathy with systemic involvement due to levamisole long-term therapy: A case report

dc.contributor.authorAoun, Bilal
dc.contributor.authorAlali, Mohammad
dc.contributor.authorDegheili, Jad A.
dc.contributor.authorSanjad, Sami A.
dc.contributor.authorVaquin, Claudine
dc.contributor.authorDonadieu, Jean
dc.contributor.authorUlinski, Tim
dc.contributor.authorTermos, Salah
dc.contributor.departmentPediatrics and Adolescent Medicine
dc.contributor.departmentSurgery
dc.contributor.departmentNephrology
dc.contributor.departmentDivision of Urology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:10:44Z
dc.date.available2025-01-24T12:10:44Z
dc.date.issued2018
dc.description.abstractBackground: Levamisole belongs to the antihelminthic class of drugs that are sometimes administered to patients with frequently relapsing or steroid-dependent nephrotic syndrome, owing to its steroid-sparing effects. Neutropenia and skin lesions, compatible with vasculitis, have been reported as drug complications, but they are rarely associated with any systemic involvement. Case presentation: We report a case of a 9-year-old Arab boy with steroid-dependent nephrotic syndrome who was treated with levamisole after his third relapse. The drug was initially well tolerated, but mild isolated neutropenia occurred 6 months after levamisole administration. This was followed by cutaneous vasculitis of both ears and the left cheek. The patient also developed hepatosplenomegaly and anemia. Levamisole was discontinued, and his disease remained in remission. All the systemic manifestations disappeared gradually over the course of 1 month. The patient remained in remission until 1 year after levamisole withdrawal, when clinical nephrosis recurred. Conclusions: Despite levamisole's being a useful drug for maintaining remission in steroid-dependent nephrotic syndrome, patients on long-term levamisole therapy should be monitored closely to prevent serious complications that can easily be resolved by simple drug withdrawal. © 2018 The Author(s).
dc.identifier.doihttps://doi.org/10.1186/s13256-018-1728-6
dc.identifier.eid2-s2.0-85050096238
dc.identifier.pmid30008268
dc.identifier.urihttp://hdl.handle.net/10938/32403
dc.language.isoen
dc.publisherBioMed Central Ltd.
dc.relation.ispartofJournal of Medical Case Reports
dc.sourceScopus
dc.subjectCutaneous vasculitis
dc.subjectHepatosplenomegaly
dc.subjectLevamisole
dc.subjectNephrotic syndrome
dc.subjectNeutropenia
dc.subjectAdjuvants, immunologic
dc.subjectCheek
dc.subjectChild
dc.subjectEar
dc.subjectGlucocorticoids
dc.subjectHumans
dc.subjectMale
dc.subjectNecrosis
dc.subjectVasculitis
dc.subjectAlanine aminotransferase
dc.subjectAspartate aminotransferase
dc.subjectComplement component c3
dc.subjectComplement component c4
dc.subjectHemoglobin
dc.subjectGlucocorticoid
dc.subjectImmunological adjuvant
dc.subjectAbdominal radiography
dc.subjectAlanine aminotransferase blood level
dc.subjectAnca associated vasculitis
dc.subjectAnemia
dc.subjectArticle
dc.subjectAspartate aminotransferase blood level
dc.subjectCase report
dc.subjectClinical article
dc.subjectClinical feature
dc.subjectDisease severity
dc.subjectDrug tolerance
dc.subjectDrug withdrawal
dc.subjectEchography
dc.subjectHemoglobin blood level
dc.subjectHepatomegaly
dc.subjectHuman
dc.subjectLong term care
dc.subjectNephrosis
dc.subjectNeutrophil count
dc.subjectPhysical examination
dc.subjectPriority journal
dc.subjectRecurrent disease
dc.subjectRelapse
dc.subjectSchool child
dc.subjectSplenomegaly
dc.subjectTreatment duration
dc.subjectTreatment response
dc.subjectVascular disease
dc.subjectChemically induced
dc.subjectPathology
dc.subjectVascularization
dc.titleDistinctive vasculopathy with systemic involvement due to levamisole long-term therapy: A case report
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2018-4108.pdf
Size:
1.49 MB
Format:
Adobe Portable Document Format